EUVIMEDEUVIMED entdecken
Übersichtsarbeit

How does TCR-T cell therapy exhibit a superior anti-tumor efficacy

Dandan Yang, Zhihui Duan, Ping Yuan, Chengming Ding, Xiaoming Dai, Guodong Chen, Daichao Wu

Biochemical and Biophysical Research Communications · 2023

DOI: 10.1016/j.bbrc.2023.149209 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Dandan Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Structural Immunology, Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University…. Hauptthemen laut MEDLINE: Receptors, Antigen, T-Cell, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 157 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province, Science and Technology Program of Hunan Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TCR-engineered T cells have achieved great progress in solid tumor therapy, some of which have been applicated in clinical trials. Deep knowledge about the current progress of TCR-T in tumor therapy would be beneficial to understand the direction. Here, we classify tumor antigens into tumor-associated antigens, tumor-specific antigens, tumor antigens expressed by oncogenic viruses, and tumor antigens caused by abnormal protein modification; Then we detail the TCR-T cell therapy effects targeting those tumor antigens in clinical or preclinical trials, and propose that neoantigen specific TCR-T cell therapy is expected to be a promising approach for solid tumors; Furthermore, we summarize the optimization strategies, such as tumor microenvironment, TCR pairing and affinity, to improve the therapeutic effect of TCR-T. Overall, this review provides inspiration for the antigen selection and therapy strategies of TCR-T in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Antigen, T-CellNeoplasmsHumansAntigens, NeoplasmCell- and Tissue-Based TherapyImmunotherapy, AdoptiveTumor Microenvironment

Stichwörter der Autor:innen

Adoptive cell therapyNeoantigenT cell receptorTCR-TTumor antigen

Substanzen

Receptors, Antigen, T-CellAntigens, Neoplasm

Autor:innen und Institutionen

  • Laboratory of Structural Immunology, Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
  • Laboratory of Structural Immunology, Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. Electronic address: 2…
  • Laboratory of Structural Immunology, Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. Electronic address: w…

Förderung

  • Natural Science Foundation of Hunan Province
  • Science and Technology Program of Hunan Province
  • National Natural Science Foundation of China
  • Hunan Provincial Science and Technology Department

Zitieren

APA

Yang, D., Duan, Z., Yuan, P., Ding, C., Dai, X., Chen, G., & Wu, D. (2023). How does TCR-T cell therapy exhibit a superior anti-tumor efficacy. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.149209

Vancouver

Yang D, Duan Z, Yuan P, Ding C, Dai X, Chen G, et al. How does TCR-T cell therapy exhibit a superior anti-tumor efficacy. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.149209

BibTeX
@article{Yang2023,
  author = {Yang, Dandan and Duan, Zhihui and Yuan, Ping and Ding, Chengming and Dai, Xiaoming and Chen, Guodong and Wu, Daichao},
  title = {How does TCR-T cell therapy exhibit a superior anti-tumor efficacy},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2023},
  doi = {10.1016/j.bbrc.2023.149209}
}
Kostenlos starten →